Multifunctional, Nanoparticle-Based, Therapies for the Treatment of Periodontal D

基于纳米颗粒的多功能治疗牙周病的疗法

• 批准号: 8127501
• 负责人: Joseph Francis Bringley
• 金额: $ 14.98万
• 依托单位: TRANSPARENT MATERIALS, LLC
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-04-01 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8127501
• 关键词: Adult; Adverse effects; Anti-Bacterial Agents; Bacterial Infections; Binding; Chemistry; Chronic; Communicable Diseases; Data; Dental; Dental Care; Dental Cementum; Dental Enamel; Dentin; Development; Dimensions; Disorder by Site; Drug Carriers; Failure; Funding; Gingiva; Gingival Crevicular Fluid; In Vitro; Industry; Infection; Intervention; Irrigation; Laboratories; Lead; Microbial Biofilms; Modality; Operative Surgical Procedures; Oral cavity; Patients; Penetration; Periodontal Diseases; Periodontal Pocket; Periodontium; Pharmaceutical Preparations; Phase; Population; Safety; Saline; Saliva; Silicon Dioxide; Small Business Innovation Research Grant; Structure; Surface; Technology; Therapeutic; Therapeutic Agents; Therapeutic Effect; Time; Tissues; Tooth Tissue; Tooth structure; United States; antimicrobial; aqueous; base; biomaterial compatibility; bisphosphonate; bone; conventional therapy; cost; design; functional group; improved; innovation; nanoparticle; nanosized; oral bacteria; prevent; prototype; restorative composite; water solution

DESCRIPTION (provided by applicant): The objective of this Phase I SBIR proposal is to provide improved therapies for the treatment of periodontal disease. Periodontal Disease is a chronic infectious disease of the oral cavity that effects about 35 % of the adult population in the United States, or slightly more than 40 million people.1-12 In severe cases, periodontal disease can lead to a failure of the underlying bone structure and necessitate surgical extraction and replacement of the teeth. In the U.S alone, the cost of treating periodontal disease was estimated at $19 billion dollars annually in 19984. The innovation proposed is to produce multifunctional, surface-modified nanoparticle carriers that are designed to bind robustly to hard tissue surfaces and bacterial biofilms, and may deliver multiple therapeutic payloads. Because the nanoparticles may bind to tissue surfaces and to bacterial biofilms, the carriers may have substantive (long lasting) therapeutic effects within the periodontal pocket, a major shortcoming of current therapies. The ability to localize and chemically attach the drug-carrier within the periodontium is a major advantage of the proposed innovation, since conventional therapies all suffer from the fact that the drugs are rapidly cleared by the turnover of gingival crevicular fluid (saliva).7 The proposed innovation, if successful, will be capable of managing multiple therapeutic chemistries and deliver them to the periodontal pocket and gingival tissues at efficacious levels over an extended period of time, without repeated intervention from a clinician. PUBLIC HEALTH RELEVANCE: Periodontal Disease is a chronic infectious disease of the oral cavity that effects about 35 % of the adult population in the United States, or slightly more than 40 million people. This SBIR seeks to overcome the shortcomings of current therapies for periodontal disease, and to provide a therapy that is capable of managing multiple therapeutic chemistries, delivering them to disease sites over an extended period of time, without the repeated intervention from a clinician.

描述(由申请人提供)：这项第一阶段SBIR提案的目标是为牙周病的治疗提供改进的治疗方法。牙周病是一种慢性口腔传染病，影响美国大约35%的成年人口，或略高于4000万人。1-12在严重的情况下，牙周病可能会导致潜在的骨骼结构失效，需要手术拔除和替换牙齿。仅在美国，19984年度牙周病的治疗费用估计为190亿美元。提议的创新是生产多功能、表面修饰的纳米颗粒载体，旨在牢固地结合到硬组织表面和细菌生物膜上，并可能提供多种治疗有效载荷。由于纳米颗粒可能结合到组织表面和细菌生物膜上，载体可能在牙周袋内具有实质性(长期)的治疗效果，这是目前治疗方法的主要缺点。将药物载体定位并以化学方式附着在牙周组织内的能力是拟议的创新的一大优势，因为传统疗法都存在这样一个问题，即药物会随着牙周沟液(唾液)的周转而迅速清除。7拟议的创新如果成功，将能够管理多种治疗化学物质，并在较长时间内有效地将它们输送到牙周袋和牙龈组织，而不需要临床医生的反复干预。 公共卫生相关性：牙周病是一种慢性口腔传染病，影响美国约35%的成年人，即略高于4000万人。这种SBIR旨在克服目前牙周病治疗方法的缺点，并提供一种能够管理多种治疗化学物质的治疗方法，在很长一段时间内将它们输送到疾病部位，而无需临床医生的反复干预。